Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

US government to pay $5.3bn for Pfizer‘s Paxlovid

If approved by the FDA, the US government will purchase 10 million courses of Pfizer’s anti-COVID protease inhibitor antiviral therapy, Paxlovid, this year and into 2022

- PMLiVE

Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn

The pharma company has been collaborating with Dicerna on its RNAi gene silencing platform since 2019

- PMLiVE

Gilead to pay $745m for three oncology programmes from Arcus Biosciences

The deal will enable Gilead to accelerate the development of candidate molecules and explore treatment combinations with long-term partner Arcus Biosciences

Using Cybersecurity to Maintain Patient Data Integrity

Christina Stokes, Founder of CyberRhythms Consulting and Writer at CyberSolace.io, explores cybersecurity in healthcare, the importance of keeping patient data safe (and the consequences of a breach), and current/future challenges...

Impetus Digital

- PMLiVE

Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)

How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch

Innovative Trials

Your Lucid Group Guide to us!

Check out our Lucid Story We are a global healthcare consultancy. We deliver life-transforming value through pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. People are...

Lucid Group Communications Limited

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

Planning for 2022?

Reach key healthcare practitioners in Infectious Disease, Aesthetic Surgery, Cardiology, Neuro-Oncology, Gerontology, Gastroenterology and more

Oxford University Press

- PMLiVE

Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’

Results announced at the American Heart Association Scientific Sessions this week suggest the drug dramatically cuts LDL cholesterol levels

- PMLiVE

AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising

The therapy – an mRNA-encoding vascular endothelial growth factor – looks promising for patients undergoing coronary artery bypass surgery

- PMLiVE

UK expands COVID-19 vaccine plans as winter approaches

The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links